BCTX Stock Overview A clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. More details
Risk Analysis + 2 more risks
See All Risk Checks {"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
Capture your thoughts, links and company narrative
BriaCell Therapeutics Corp. Competitors Price History & Performance
Summary of share price highs, lows and changes for BriaCell Therapeutics Historical stock prices Current Share Price CA$3.43 52 Week High CA$56.70 52 Week Low CA$3.33 Beta 1.87 1 Month Change -43.23% 3 Month Change -61.91% 1 Year Change -93.33% 3 Year Change -97.01% 5 Year Change -98.73% Change since IPO -99.40%
Recent News & Updates BriaCell Therapeutics Corp. has completed a Follow-on Equity Offering in the amount of CAD 3.05 million. Feb 06
BriaCell Therapeutics Corp. has filed a Follow-on Equity Offering. Feb 05
Briacell Announces Resolution of Lung Metastasis in First Patient Treated with Bria-OTS
New major risk - Revenue and earnings growth Feb 03
Insufficient new directors Feb 02
New major risk - Financial position Dec 18 See more updates BriaCell Therapeutics Corp. has completed a Follow-on Equity Offering in the amount of CAD 3.05 million. Feb 06
BriaCell Therapeutics Corp. has filed a Follow-on Equity Offering. Feb 05
Briacell Announces Resolution of Lung Metastasis in First Patient Treated with Bria-OTS
New major risk - Revenue and earnings growth Feb 03
Insufficient new directors Feb 02
New major risk - Financial position Dec 18 BriaCell Therapeutics Corp. has completed a Composite Units Offering in the amount of $5.55 million. Dec 13
BriaCell Therapeutics Corp. has completed a Composite Units Offering in the amount of $5.55 million.
BriaCell Receives Green-Light from Data Safety Monitoring Board for Its Phase 3 Study in Metastatic Breast Cancer Dec 02
Insufficient new directors Dec 01
BriaCell Therapeutics Corp. Accepts the Resignation of Marc Lustig from the Board of Directors Nov 26
Briacell Announces First Patient Dosed with Bria-OTS™ in Metastatic Breast Cancer Study Nov 21
BriaCell Therapeutics Corp., Annual General Meeting, Jan 23, 2025 Nov 18
BriaCell Therapeutics Corp. Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference Nov 08
Briacell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data Oct 22
BriaCell Therapeutics Corp. Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Pivotal Study Oct 15 BriaCell Therapeutics Corp. has filed a Follow-on Equity Offering. BriaCell Therapeutics Corp. Reports 100% Resolution of Brain Metastasis in Breast Cancer Patient with "Eye-Bulging" Tumor
Insufficient new directors Oct 01
Price target decreased by 14% to US$15.00 Sep 19
BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients Sep 18
New major risk - Financial data availability Sep 16
New major risk - Shareholder dilution Sep 15 BriaCell Therapeutics Corp. has completed a Follow-on Equity Offering in the amount of $8.50425 million. Sep 13
BriaCell Therapeutics Corp. has filed a Follow-on Equity Offering in the amount of $8.50425 million.
BriaCell Therapeutics Corp. Announces Positive Overall Survival Data of its Phase 2 Clinical Study of Bria-IMT in Combination with an Immune Check Point Inhibitor Sep 11
BriaCell Announces Positive Pre-IND Meeting with FDA for Bria-PROS+ for Prostate Cancer Sep 10
BriaCell Therapeutics Receives Deficiency Letter from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement Aug 26
BriaCell Therapeutics Corp. Quadruples Progression Free Survival (Pfs) in Patient with "Eye-Bulging" Metastatic Breast Cancer Jul 19
BriaCell Therapeutics Receives Letter from Nasdaq Due to Non-Compliance with the Minimum Market Value of Listed Securities Requirement Pursuant to Nasdaq Listing Rule 5550(b)(2) Jul 06
Briacell Therapeutics Corp. Presents Clinical Efficacy Data At ASCO 2024 Jun 05
BriaCell Therapeutics Corp. Initiates Patient Enrollment in First-In-Human Study of Bria-Ots in Advanced Metastatic Breast Cancer May 31
New minor risk - Shareholder dilution May 23
Independent Director recently bought US$2.0m worth of stock May 22 BriaCell Therapeutics Corp. has completed a Follow-on Equity Offering in the amount of $4.80586 million. May 18
BriaCell Therapeutics Corp. has filed a Follow-on Equity Offering in the amount of $5 million. May 16
BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer Apr 10
New major risk - Negative shareholders equity Mar 20
BriaCell Therapeutics Corp. Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case Feb 08
Briacell Therapeutics Corp. Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates Gmp Manufacturing Feb 07
BriaCell Therapeutics Corp. Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients Dec 29
BriaCell Therapeutics Corp. Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate Refractory Patient Subset Dec 20
BriaCell Therapeutics Corp. Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS Dec 06
BriaCell Therapeutics Corp., Annual General Meeting, Jan 30, 2024 Dec 02
BriaCell Therapeutics Corp. Announces Anew Remarkable Responder in Phase 2 Study of the Bria-IMT Combination Regimen Dec 01
BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS™ IND Nov 04
New minor risk - Share price stability Nov 04
New major risk - Financial position Oct 27
BriaCell Therapeutics Corp. Forms Medical Advisory Board of Distinguished Breast Cancer Specialists to Advance its Lead Oncology Candidate Oct 26
BriaCell Therapeutics Corp. Initiates Pivotal Phase 3 Study of Bria-Imt™ in Advanced Metastatic Breast Cancer Oct 05
BriaCell Therapeutics Corp. Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer Sep 09 BriaCell Therapeutics Corp. completed the Spin-Off of 33.33% stake in Pre-Clinical Assets of BriaCell Therapeutics Corp.
Briacell Receives National Cancer Institute Grant to Advance Its Bria-Ots™ Immunotherapy for Cancer Aug 17
FDA Approves BriaCell’s Pivotal Registrational Study Design in Advanced Metastatic Breast Cancer Jun 28
BriaCell Therapeutics Corp. Announces Positive End of Phase II Meeting with the FDA for Bria-IMT™ Combination in Advanced Metastatic Breast Cancer Jan 19
Independent Chairman of the Board recently bought US$118k worth of stock Dec 23
BriaCell Therapeutics Corp., Annual General Meeting, Jan 24, 2023 Nov 18 BriaCell Therapeutics Corp. Reports Positive Breast Cancer Efficacy Data with Bria-IMT™ Immunotherapy Treatment at SITC Annual Meeting Nov 11
BriaCell Announces Successful Completion of Phase I Portion of Clinical Study in Advanced Breast Cancer; Randomized Phase II Efficacy Evaluation Progressing Oct 22
BriaCell Therapeutics Corp. Announces New Clinical Trial Site to Bring Novel Cancer Treatments to Advanced Breast Cancer Patients Oct 13
BriaCell Therapeutics Corp. Secures License for A Promising Novel Anti-Cancer Agent Aug 05
BriaCell stock rises on license deal for anti-cancer agent Aug 04
BriaCell partners with Waisman Biomanufacturing to make & supply prostate cancer therapy Jul 05
BriaCell, Harvard enter research agreement to identify targets for cancer treatments Jun 29
BriaCell Therapeutics Corp. Receives FDA Fast Track Approval for Targeted Breast Cancer Immunotherapy Apr 14
BriaCell Advances Preparatory Work for New Bria-OTS Breast Cancer Clinical Trial Apr 08
High number of new directors Mar 29
BriaCell Therapeutics Corp. Adds Two Clinical Trial Sites to Accelerate Patient Enrollment Mar 01
BriaCell Therapeutics Corp. Appoints Alexander Kharazi to Its Scientific Advisory Board Feb 24
Director recently bought US$433k worth of stock Feb 19 Shareholder Returns BCTX US Biotechs US Market 7D -16.3% -4.2% 0.2% 1Y -93.3% -3.0% 23.1%
See full shareholder returns
Return vs Industry: BCTX underperformed the US Biotechs industry which returned -4.5% over the past year.
Return vs Market: BCTX underperformed the US Market which returned 21% over the past year.
Price Volatility Is BCTX's price volatile compared to industry and market? BCTX volatility BCTX Average Weekly Movement 23.0% Biotechs Industry Average Movement 11.4% Market Average Movement 5.9% 10% most volatile stocks in US Market 18.3% 10% least volatile stocks in US Market 3.0%
Stable Share Price: BCTX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BCTX's weekly volatility (23%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.
Show more BriaCell Therapeutics Corp. Fundamentals Summary How do BriaCell Therapeutics's earnings and revenue compare to its market cap? BCTX fundamental statistics Market cap US$13.47m Earnings (TTM ) -US$16.60m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) BCTX income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$16.60m Earnings -US$16.60m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/11 10:29 End of Day Share Price 2025/02/11 00:00 Earnings 2024/10/31 Annual Earnings 2024/07/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources BriaCell Therapeutics Corp. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Emily Bodnar H.C. Wainwright & Co. Ashok Kumar ThinkEquity LLC
